Supernus Pharmaceuticals Files 8-K for Shareholder Vote & Exhibits
Ticker: SUPN · Form: 8-K · Filed: Jun 17, 2025 · CIK: 1356576
| Field | Detail |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. (SUPN) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, shareholder-vote
Related Tickers: SUPN
TL;DR
SUPN filed an 8-K for shareholder votes and financials - check for updates.
AI Summary
On June 16, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report to announce the submission of matters to a vote of security holders and to file financial statements and exhibits. The filing was made on June 17, 2025, and pertains to the company's operations as of June 16, 2025. Supernus Pharmaceuticals, Inc. is incorporated in Delaware and its principal executive offices are located in Rockville, MD.
Why It Matters
This filing indicates that Supernus Pharmaceuticals is proceeding with important corporate actions requiring shareholder approval and is providing updated financial information, which is crucial for investors to assess the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing for corporate governance and financial reporting, not indicating any immediate operational or financial distress.
Key Numbers
- 001-35518 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20-2590184 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Supernus Pharmaceuticals, Inc. (company) — Registrant
- June 16, 2025 (date) — Date of earliest event reported
- June 17, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Rockville, MD (location) — Principal Executive Offices
FAQ
What specific matters are being submitted for a vote of security holders?
The filing indicates that matters are being submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What financial statements and exhibits are being filed?
The filing states that financial statements and exhibits are being filed, but the specific content of these documents is not detailed in the provided text.
What is the significance of the 'Date as of change' being June 17, 2025?
The 'Date as of change' being June 17, 2025, likely refers to the date the filing was officially processed or updated in the SEC system, aligning with the filing date.
What is Supernus Pharmaceuticals, Inc.'s primary business?
Supernus Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 17, 2025 regarding SUPERNUS PHARMACEUTICALS, INC. (SUPN).